Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $23.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 233.82% from the stock’s previous close. A number of other equities […]
More Stories
MX Player for PC: How the Android Video Player Behaves on a Desktop Screen
Most people know MX Player as the app that finally played that one weird video file their phone refused to...
Release Window for Blue Eye Samurai Season 2? Latest Updates and More
Blue Eye Samurai Season 2 is releasing soon on the most popular streaming platform, Netflix. If you are also a...
What is the Release Date for GTA 6? System Requirements and Updated Features
GTA 6 is finally arriving! After years of delays and speculation, Rockstar finally confirmed the game’s launch by the end...
Upcoming Korean Drama: 100 Days of Deception Release Date, Plot, and More
K-drama fans have been longing for a historical action-romance series. Are you also one of those fans who are desperately...
Custom Web Application Development Process: Benefits, Example, Process, and Cost
For a developing business, it sometimes becomes difficult to manage spreadsheets, teams, and SaaS tools. Are you also facing the...
Netflix’s Upcoming Documentary: A Child of My Own Release Date and More
Are you also interested in watching the real-life documentary? If yes, then this blog is for you. One of the...